805 related articles for article (PubMed ID: 32681845)
1. Coagulopathy in COVID-19: Focus on vascular thrombotic events.
Shi W; Lv J; Lin L
J Mol Cell Cardiol; 2020 Sep; 146():32-40. PubMed ID: 32681845
[TBL] [Abstract][Full Text] [Related]
2. Thromboembolic events and Covid-19.
Ribes A; Vardon-Bounes F; Mémier V; Poette M; Au-Duong J; Garcia C; Minville V; Sié P; Bura-Rivière A; Voisin S; Payrastre B
Adv Biol Regul; 2020 Aug; 77():100735. PubMed ID: 32773098
[TBL] [Abstract][Full Text] [Related]
3. Venous Thromboembolism Complicated with COVID-19: What Do We Know So Far?
Tal S; Spectre G; Kornowski R; Perl L
Acta Haematol; 2020; 143(5):417-424. PubMed ID: 32396903
[TBL] [Abstract][Full Text] [Related]
4. COVID-19 and Hypercoagulability.
Sholzberg M
Clin Adv Hematol Oncol; 2020 Jul; 18(7):386-389. PubMed ID: 32903249
[No Abstract] [Full Text] [Related]
5. COVID-19 coagulopathy: An in-depth analysis of the coagulation system.
Martín-Rojas RM; Pérez-Rus G; Delgado-Pinos VE; Domingo-González A; Regalado-Artamendi I; Alba-Urdiales N; Demelo-Rodríguez P; Monsalvo S; Rodríguez-Macías G; Ballesteros M; Osorio-Prendes S; Díez-Martín JL; Pascual Izquierdo C
Eur J Haematol; 2020 Dec; 105(6):741-750. PubMed ID: 32749010
[TBL] [Abstract][Full Text] [Related]
6. IP-10 and MCP-1 as biomarkers associated with disease severity of COVID-19.
Chen Y; Wang J; Liu C; Su L; Zhang D; Fan J; Yang Y; Xiao M; Xie J; Xu Y; Li Y; Zhang S
Mol Med; 2020 Oct; 26(1):97. PubMed ID: 33121429
[TBL] [Abstract][Full Text] [Related]
7. Foreword for the special issue advances in COVID-19: Biology and clinic.
McCubrey JA; Akula SM; Payrastre B
Adv Biol Regul; 2020 Aug; 77():100744. PubMed ID: 32773104
[No Abstract] [Full Text] [Related]
8. Thromboembolic events and apparent heparin resistance in patients infected with SARS-CoV-2.
Beun R; Kusadasi N; Sikma M; Westerink J; Huisman A
Int J Lab Hematol; 2020 Jun; 42 Suppl 1(Suppl 1):19-20. PubMed ID: 32311843
[No Abstract] [Full Text] [Related]
9. Pulmonary Embolism and Increased Levels of d-Dimer in Patients with Coronavirus Disease.
Griffin DO; Jensen A; Khan M; Chin J; Chin K; Saad J; Parnell R; Awwad C; Patel D
Emerg Infect Dis; 2020 Aug; 26(8):1941-1943. PubMed ID: 32348233
[TBL] [Abstract][Full Text] [Related]
10. Peptides: Prospects for Use in the Treatment of COVID-19.
Khavinson V; Linkova N; Dyatlova A; Kuznik B; Umnov R
Molecules; 2020 Sep; 25(19):. PubMed ID: 32987757
[TBL] [Abstract][Full Text] [Related]
11. Viral Coagulopathy in Patients With COVID-19: Treatment and Care.
Kipshidze N; Dangas G; White CJ; Kipshidze N; Siddiqui F; Lattimer CR; Carter CA; Fareed J
Clin Appl Thromb Hemost; 2020; 26():1076029620936776. PubMed ID: 32687449
[TBL] [Abstract][Full Text] [Related]
12. Thrombocytopathy vs Platelet hyper-reactivity in COVID-19: diverse pathologies, disease outcomes and therapeutic implications.
Tafazoli A; Anil Kumar S; Othman M
Platelets; 2022 Jan; 33(1):48-53. PubMed ID: 34847829
[TBL] [Abstract][Full Text] [Related]
13. Understanding the andromeda strain - The role of cytokine release, coagulopathy and antithrombin III in SARS-CoV2 critical illness.
Mir N; D'Amico A; Dasher J; Tolwani A; Valentine V
Blood Rev; 2021 Jan; 45():100731. PubMed ID: 32829961
[TBL] [Abstract][Full Text] [Related]
14. COVID-19-Associated Coagulopathy and Inflammatory Response: What Do We Know Already and What Are the Knowledge Gaps?
Görlinger K; Dirkmann D; Gandhi A; Simioni P
Anesth Analg; 2020 Nov; 131(5):1324-1333. PubMed ID: 33079850
[TBL] [Abstract][Full Text] [Related]
15. A proof of evidence supporting abnormal immunothrombosis in severe COVID-19: naked megakaryocyte nuclei increase in the bone marrow and lungs of critically ill patients.
Roncati L; Ligabue G; Nasillo V; Lusenti B; Gennari W; Fabbiani L; Malagoli C; Gallo G; Giovanella S; Lupi M; Salviato T; Paolini A; Costantini M; Trenti T; Maiorana A
Platelets; 2020 Nov; 31(8):1085-1089. PubMed ID: 32857624
[TBL] [Abstract][Full Text] [Related]
16. COVID-19: Review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking.
Magro G
Virus Res; 2020 Sep; 286():198070. PubMed ID: 32569708
[TBL] [Abstract][Full Text] [Related]
17. Cytokine Storm: Is it the only major death factor in COVID-19 patients? Coagulation role.
Magro G
Med Hypotheses; 2020 Sep; 142():109829. PubMed ID: 32428809
[No Abstract] [Full Text] [Related]
18. COVID-19: Coagulopathy, Risk of Thrombosis, and the Rationale for Anticoagulation.
Miesbach W; Makris M
Clin Appl Thromb Hemost; 2020; 26():1076029620938149. PubMed ID: 32677459
[TBL] [Abstract][Full Text] [Related]
19. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study.
Helms J; Tacquard C; Severac F; Leonard-Lorant I; Ohana M; Delabranche X; Merdji H; Clere-Jehl R; Schenck M; Fagot Gandet F; Fafi-Kremer S; Castelain V; Schneider F; Grunebaum L; Anglés-Cano E; Sattler L; Mertes PM; Meziani F;
Intensive Care Med; 2020 Jun; 46(6):1089-1098. PubMed ID: 32367170
[TBL] [Abstract][Full Text] [Related]
20. Pathogenesis and Treatment Strategies of COVID-19-Related Hypercoagulant and Thrombotic Complications.
Haimei MA
Clin Appl Thromb Hemost; 2020; 26():1076029620944497. PubMed ID: 32722927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
